These mutations can co-exist with other known driver mutations in lung adenocarcinoma, including EGFR and KRAS and in the setting of acquired EGFR TKI resistance (49, 50), suggesting that this may not be a driver mutation in itself. The gene discussed is KRAS; the disease is lung adenocarcinoma.